Research
FORUM TRANSCRIPT

CRO Industry – Q4 2022 Update & Competitive Differentiation

  • Public Equity
  • Healthcare
  • North America
PREMIUM

Specialist

Founder & consultant at a CRO consultancy

Agenda

  • Trends and Developments in the CRO (contract research organisation) market, highlighting Iqvia (NYSE: IQV), PPD (NASDAQ: PPD), Icon (NASDAQ: ICLR), Syneos Health (NASDAQ: SYNH), and Medpace (NASDAQ: MEDP)
  • Purchasing criteria for pharmaceutical and biotech customers and differentiators for large market CRO services, highlighting expertise in a particular therapeutic area, global geographic reach and pre-clinical and clinical capabilities
  • CROs’ DCT (decentralised clinical trial) capabilities, discussing remote technology and data collection
  • M&A in the CRO sector – Icon’s July 2021 acquisition of PRA and projected strategic M&A opportunities as CRO industry grows
  • Industry contracting models, discussing product-based services vs outcome-based models, plus 12-18-month CRO market outlook and increased adaptation of emerging technologies

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo